

10031915.0118

COPY

JC10 Rec'd PCT 18 JAN 2002

FORM PTO-100 OFFICE		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK	ATTORNEY'S DOCKET NUMBER FF-0722 USN
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (if known, see 37 CFR 1.5) TO BE ASSIGNED 10/031915
INTERNATIONAL APPLICATION NO. PCT/US00/09468	INTERNATIONAL FILING DATE 21 July 2000	PRIORITY DATE CLAIMED 21 July 1999	
TITLE OF INVENTION CELL CYCLE AND PROLIFERATION PROTEINS			
APPLICANT(S) FOR DO/EO/US BILLMAN, Jennifer; LAI, Freeth; TANG, Y. Tzu; YUE, Henry; AU-YOUNG, Janice; BANDMAN, Olga; AZIMZAI, Yalda; YANG, Junning; LI, Dying Aina M.; BAUGHN, Mariah R.; PATTERSON, Chandra; SHAH, Porri			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is the FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371 (f)).</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau)</p> <p>b. <input type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input type="checkbox"/> have not been made and will not be made.</p> <p>a. <input type="checkbox"/> attached hereto Article 34 Amendment</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>			
Items 11 to 16 below concern document(s) or information included:			
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.27 and 3.51 is included.			
13. <input checked="" type="checkbox"/> A FIRST preliminary amendment, as follows:			
<p>Canceled in this application original claims #12, 14, 18, 20, 21, 23, 24, 27 before calculating the filing fee, without prejudice or disclaimer. Applicants submit that these claims were included in the application as filed in the interest of providing notice to the public of certain specific subject matter intended to be claimed, and are being canceled at this time in the interest of reducing filing costs. Applicants expressly state that these claims are not being canceled for reasons related to patentability, and are in fact fully supported by the specification as filed. Applicants expressly reserve the right to reinstate these claims or to add other claims during prosecution of this application or a continuation or divisional application. Applicants expressly do not disclaim the subject matter of any invention disclosed herein which is not set forth in the instantly filed claims.</p> <p><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p>			
14. <input type="checkbox"/> A substitute specification.			
15. <input type="checkbox"/> A change of power of attorney and/or address letter.			
16. <input checked="" type="checkbox"/> Other items or information:			
1) Transmittal Letter (2 pp, in duplicate)			
2) Return Postcard			
3) Express Mail Label No.: EY 856149 089 US			
4) Sequence Listing Statement and Diskette			
5) Article 34 Amendment			


JAN. 12. 2004 6:23PM

6508454166

NO. 8000 P. 43

10031915.011802

JC15 Rec'd PCT/PTO 18 JAN 2002

U.S. APPLICATION NO. (if known, see 37 CFR 1.37) TO BE ALIGNED WITH: 10031915		INTERNATIONAL APPLICATION NO.: PCT/US00/12946		ATTORNEY'S DOCKET NUMBER PCT-0722 USN	
<p>17. The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(3))</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or IPO.....\$1000.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or IPO.....\$3860.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$710.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00</p>					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$710.00	
Surcharge of \$150.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	20 =	0	X \$ 18.00	\$	
Independent Claims	3 =	0	X \$ 60.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL				\$710.00	
Processing fee of \$250.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$710.00	
Fee for recording the enclosed assignment (37 CFR 1.21(b)). The assignment must be accompanied by the appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					
TOTAL FEES ENCLOSED =				\$710.00	
				Amount to be Refunded	\$
				Charged	\$
<p>a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. <u>09-0108</u> in the amount of \$710.00 to cover the above fees.</p> <p>c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayments to Deposit Account No. <u>09-0108</u>. A duplicate copy of this sheet is enclosed.</p>					
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>					
SEND ALL CORRESPONDENCE TO:					
INCYTE GENOMICS, INC. 3160 Foster Drive Palo Alto, CA 94304			 SIGNATURE		
NAME: Diana Handet-Cox					
REGISTRATION NUMBER: 31,302					
DATE: 18 January 2002					

Docket No.: PF-0722 USN

Certificate of Transmission

I hereby certify that this paper is being facsimile transmitted to the attention of Examiner Karen Cochrane Carlson, Group Art Unit 1653, U.S. Patent and Trademark Office to Facsimile No. (703) 872-9306 on January 12, 2004.

By:  Printed: Lyza Finellar

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: CELL CYCLE AND PROLIFERATION PROTEINS

Serial No.: 10/031,915

Filing Date: January 18, 2002

Examiner: Carlson, K.

Group Art Unit: 1653

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

118301

1

10/031,915

Docket No.: PF-0722 USN

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108.

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,

INCYTE CORPORATION

Date: January 12, 2004

Susan K. Sather

Susan K. Sather

Reg. No. 44,316

Direct Dial Telephone: (650) 845-4646

Customer No.: 27904
3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

Sheet 1 of 1

U.S. Department of Commerce, Patent and Trademark Office				Atty Docket No.		Serial No.	
				PF-0722 USN		10/031,915	
LIST OF REFERENCES CITED BY APPLICANTS				Applicant(s)			
(Use several sheets if necessary)				Hillman et al.			
				Filing Date		Group	
				January 18, 2002		1653	
U.S. Patent Documents							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
Foreign Patent Documents							
						Translation	
		Document Number	Date	Country	Class	Subclass	Yes No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	1	Koga, H. et al., (GI 3811111) Genbank Sequence Database (Accession AAC69438), National Center for Biotechnology Information: National Library Of Medicine, Bethesda, Maryland 20849 (November 24, 2000)					
Examiner			Date Considered				
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPFP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.</p>							